| HOME >> MEDICINE >> TECHNOLOGY |
(1,806)28(1,766)1,016 Total interest and other expense, net
(5,353)(5,810)(26,425)(28,179)Net loss
(23,682)(28,241)(109,224)(124,534)Deemed dividend related to beneficial conversion feature of convertible preferred stock
00(2,260)0Net loss allocable to common stockholders
$(23,682)$(28,241)$(111,484)$(124,534)Net loss per share allocable to common stockholders:Basic
$(0.16)$(0.23)$(0.80)$(1.14)Diluted
$(0.16)$(0.23)$(0.80)$(1.14)Shares used in calculating net loss per share allocable to common stockholders:Basic
146,028121,415139,171109,573Diluted
146,028121,415139,171109,573Note: The Condensed Consolidated Statements of Operations has been derived from the audited financial statements for the year ended December 31, 2010 and from the unaudited financial statements for the year ended December 31, 2011.Arena Pharmaceuticals, Inc.Condensed Consolidated Balance Sheet Data(In thousands)December 31, 2011December 31, 2010**Assets Cash, cash equivalents & short-term investments
$ 57,632$ 150,669 Accounts receivable
6073,499 Other current assets
2,0212,638 Land, property & equipment, net
82,06691,533 Acquired technology & other non-current assets
14,80318,023Total assets
$ 157,129$ 266,362Liabilities and Stockholders' Equity Accounts payable and accrued liabilities
$
9,574$ 10,680 Total deferred revenues
44,68248,077 Total derivative liabilities
1,6172,271 Total note payable to Siegfried
010,361 Total note payable to Deerfield **
14,69837,777 Total lease financing obligations & other long-term liabilities
75,99677,181 Total stockholders' equity
10,56280,015Total liabilities & stockholders' equity
$ 157,129$ 266,362* The Condensed Consolidated Balance Sheet Data has been derived from the audited financial sta
'/>"/>
| SOURCE Arena Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved |